Literature DB >> 23226665

Vitamin D and breast cancer.

Ashraf Karbasi1, Amin Saburi.   

Abstract

Entities:  

Year:  2012        PMID: 23226665      PMCID: PMC3510939          DOI: 10.4103/2230-8210.103039

Source DB:  PubMed          Journal:  Indian J Endocrinol Metab        ISSN: 2230-9500


× No keyword cloud information.
Sir, We read with a great interest Imtiaz et al.'s paper published recently in Indian journal of Endocrinology and metabolism.[1] They skillfully design a study to determine a possible relationship between grade/stage of breast cancer (BC) and serum level of Vitamin D. Finally, they concluded that “almost all patients with breast cancer were vitamin D deficient and tumor characteristics did not show any significant associations with serum levels of vitamin D.” Although this issue is a hot topic in endocrinology and oncology but in this study there are some concerns which undermine the results to make a definite conclusion. One of the most important queries in this study is amount of cases. We can claim that if the difference between two groups (BC and Healthy) was not significant, it could because of small amount of sample size. Therefore, the authors should estimate “power” of study to rule out this query. Secondly, matching cases between two groups in an endocrinology study is critical. The authors matched groups in terms of age but menopausal status, age of menopause, race, menopausal hormone therapy, marital status, occupation, OCP use and etc should be matched. They demonstrated some demographic data for mentioned confounding factors but they did not state P-value for it to confirm matching between two groups. Thirdly, they measured only 25 (OH)2 vitamin D although it seems that measuring total 25-OH vitamin D levels (D (2) + D (3))can present a more valid serum level of vitamin D.[2] Also, some documents define terms of vitamin D deficiency and insufficiency different with this study which can justify differences between this study and them.[2] Moreover, Secondary cause of vitamin D deficiency in patients with BC such as Idiopathic hypercalciuria, primary hyperparathyroidism and normocalcemic hyperparathyroidism should be considered in these patients before any conclusion which was not enough considered by the authors.[3] A newly considered aspect of relation between Vitamin D and neoplastic disorders such as breast cancer is role of Vitamin D Binding Protein (VDBP) in these diseases.[4] It was confirmed that lower level of vitamin D can be associated with higher incidence and worse prognosis.[5] The anti-neoplastic role of vitamin D can be due to enhancing effect of vitamin D on immune system which was weaken by alpha-N-acetylgalactosaminidase. Vitamin D binding proteins such as S100 and GC proteins group have a significant role in malignancy and neoplasm progression. The level of these proteins may be affected by serum level of vitamin D.[6] However, Gc-MAF (macrophage activating factor) as an activated vitamin D like proteins is a useful treatment for breast cancer which is less considered previously.[7] Therefore, when we want to discussed about the role of vitamin D in neoplastic disorders, it is also better to talk about its role in enhancing the immune system as system biology. Further study focusing on therapeutic effects of vitamin D derivates either as nutritional supplement for vitamin deficiency and also immunotherapy is required.
  7 in total

1.  The new aspects of immunotherapy in prostate cancer.

Authors:  Mostafa Ghanei; Majid Shohrati; Amin Saburi
Journal:  Cancer Immunol Immunother       Date:  2012-06-27       Impact factor: 6.968

Review 2.  Gc protein (vitamin D-binding protein): Gc genotyping and GcMAF precursor activity.

Authors:  Hideko Nagasawa; Yoshihiro Uto; Hideyuki Sasaki; Natsuko Okamura; Aya Murakami; Shinichi Kubo; Kenneth L Kirk; Hitoshi Hori
Journal:  Anticancer Res       Date:  2005 Nov-Dec       Impact factor: 2.480

3.  The effect of various vitamin D supplementation regimens in breast cancer patients.

Authors:  Luke J Peppone; Alissa J Huston; Mary E Reid; Randy N Rosier; Yousef Zakharia; Donald L Trump; Karen M Mustian; Michelle C Janelsins; Jason Q Purnell; Gary R Morrow
Journal:  Breast Cancer Res Treat       Date:  2011-03-08       Impact factor: 4.872

4.  Prevalence of secondary causes of bone loss among breast cancer patients with osteopenia and osteoporosis.

Authors:  Pauline M Camacho; Amit S Dayal; Josefina L Diaz; Fadi A Nabhan; Monica Agarwal; John G Norton; Patricia A Robinson; Kathy S Albain
Journal:  J Clin Oncol       Date:  2008-10-27       Impact factor: 44.544

5.  Serum 25-hydroxyvitamin D and risk of post-menopausal breast cancer--results of a large case-control study.

Authors:  Sascha Abbas; Jakob Linseisen; Tracy Slanger; Silke Kropp; Elke Jonny Mutschelknauss; Dieter Flesch-Janys; Jenny Chang-Claude
Journal:  Carcinogenesis       Date:  2007-10-31       Impact factor: 4.944

6.  Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage activating factor (GcMAF).

Authors:  Nobuto Yamamoto; Hirofumi Suyama; Nobuyuki Yamamoto; Naofumi Ushijima
Journal:  Int J Cancer       Date:  2008-01-15       Impact factor: 7.396

7.  Vitamin D deficiency in newly diagnosed breast cancer patients.

Authors:  Saba Imtiaz; Neelam Siddiqui; Syed Abbas Raza; Asif Loya; Aasim Muhammad
Journal:  Indian J Endocrinol Metab       Date:  2012-05
  7 in total
  2 in total

1.  SNP rs11185644 of RXRA gene is identified for dose-response variability to vitamin D3 supplementation: a randomized clinical trial.

Authors:  Mingzhi Zhang; Lan-Juan Zhao; Yu Zhou; Rhamee Badr; Patrice Watson; An Ye; Boting Zhou; Jigang Zhang; Hong-Wen Deng; Robert R Recker; Joan M Lappe
Journal:  Sci Rep       Date:  2017-01-12       Impact factor: 4.379

Review 2.  Promising role for Gc-MAF in cancer immunotherapy: from bench to bedside.

Authors:  Ehsan Saburi; Amin Saburi; Mostafa Ghanei
Journal:  Caspian J Intern Med       Date:  2017
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.